TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Share Price Deutsche Boerse AG
Equities
TKD
JP3463000004
Pharmaceuticals
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.42 EUR | +2.63% |
|
+1.52% | -6.41% |
| 24/06 | Hutchmed China notes Takeda obtains EU approval for Fruzaqla | AN |
| 24/06 | Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators | MT |
| Sales 2024 | 4,26400Cr 2.67TCr 2.49TCr 2,23000Cr | Sales 2025 * | 4,28100Cr 2.68TCr 2.5TCr 2,23900Cr | Capitalization | 6,42500Cr 4.03TCr 3.75TCr 3,36100Cr |
|---|---|---|---|---|---|
| Net income 2024 | 14TCr 90Cr 84Cr 7.54TCr | Net income 2025 * | 9.26TCr 58Cr 54Cr 4.84TCr | EV / Sales 2024 | 2.57 x |
| Net Debt 2024 | 4,38600Cr 2.75TCr 2.56TCr 2,29400Cr | Net Debt 2025 * | 4,18900Cr 2.63TCr 2.45TCr 2,19100Cr | EV / Sales 2025 * | 2.48 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
70.7
x | Employees | 49,095 |
| Yield 2024 |
4.49% | Yield 2025 * |
4.76% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | +2.63% | ||
| 1 week | +1.52% | ||
| Current month | -1.67% | ||
| 1 month | -0.04% | ||
| 3 months | -9.44% | ||
| 6 months | -4.33% | ||
| Current year | -6.41% |
1 week
23.37
24.09
1 month
23.3725.19
Current year
23.3727.59
1 year
23.3730.99
3 years
23.3731.14
5 years
23.2037.63
10 years
23.2050.45
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 24.09 | +1.22% | 50 |
| 24/24/24 | 23.8 | +0.93% | 0 |
| 21/24/21 | 23.58 | +0.64% | 0 |
| 20/24/20 | 23.43 | +0.26% | 212 |
| 19/24/19 | 23.37 | -1.52% | 100 |
Delayed Quote Deutsche Boerse AG, June 25, 2024 at 11:31 am IST
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
26/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,095
JPY
Average target price
4,744
JPY
Spread / Average Target
+15.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.70% | 80TCr | |
| +41.58% | 63TCr | |
| -4.86% | 36TCr | |
| +21.96% | 34TCr | |
| +11.47% | 31TCr | |
| +17.72% | 25TCr | |
| +4.46% | 23TCr | |
| +13.13% | 22TCr | |
| +10.46% | 17TCr |
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
